Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Neurol Int ; 16(2): 356-369, 2024 Mar 18.
Article in English | MEDLINE | ID: mdl-38525706

ABSTRACT

BACKGROUND: Headache disorders have been associated with anxiety and depressive disorders. The aim of this study was to assess symptoms of anxiety and depression in a large sample of individuals with different headache disorders (HDs) in order to determine whether their frequency differs by headache type. METHODS: Consecutive individuals with headache attending a headache outpatient clinic were interviewed with the HAM-D and HAM-A, along with age, sex, and education matched non-headache individuals. RESULTS: Individuals numbering 2673 with headache (females 71.2%) and 464 non-headache individuals (females 70.9%) were interviewed (with participation rates of 98.3% and 91.0%, respectively). Migraine was diagnosed in 49.7%, tension-type headache in 38%, cluster headache 5.2%, and medication overuse (MO) in 21.8%. Participants with HD scored more in HAM-A (OR = 4.741, CI95%: 3.855-5.831, p < 0.001) and HAM-D scales (OR = 2.319, CI95%: 1.892-2.842, p < 0.001) than non-headache individuals. Participants with chronic HDs (≥15 days with headache for ≥3 consecutive months; 52.5%) scored higher for both HAM-A (OR = 1.944, CI95%: 1.640-2.303, p < 0.001) and HAM-D (OR = 1.625, CI95%: 1.359-1.944, p < 0.001) than those with episodic HDs (33.1%), as did participants with MO vs. participants without MO (OR = 3.418, CI95%: 2.655-4.399, p < 0.001 for HAM-A, OR = 3.043, CI95%: 2.322-3.986, p < 0.001 for HAM-D). Female and low-educated participants scored higher on both scales. CONCLUSION: Because symptoms of anxiety and depression are substantial in people with HD, the treating physicians should look out for such symptoms and manage them appropriately.

2.
J Headache Pain ; 18(1): 102, 2017 Oct 06.
Article in English | MEDLINE | ID: mdl-28986900

ABSTRACT

BACKGROUND: We aimed to explore patients' preferences for headache treatments with a self-administered questionnaire including the Q-No questionnaire for nocebo. METHODS: Questionnaires from 514 outpatients naïve to neurostimulation and monoclonal antibodies were collected. RESULTS: Patients assessed that the efficacy of a treatment is more important than safety or route of administration. They preferred to use an external neurostimulation device for both acute (67.1%) and preventive treatment (62.8%). Most patients preferred to take a pill (86%) than any other drug given parenterally for symptomatic pharmaceutical treatment. For preventive pharmaceutical treatment, most patients preferred to take a pill once per day (52%) compared to an injection either subcutaneously or intravenously each month (9% and 4%), or three months (15% and 11%). 56.6% of all participants scored more than 15 in Q-No questionnaire indicating potential nocebo behaviors that contributed significantly in their choices. CONCLUSION: These patient preferences along with efficacy and safety data may help physicians better choose the right treatment for the right person.


Subject(s)
Headache/prevention & control , Headache/psychology , Patient Preference/psychology , Surveys and Questionnaires , Adult , Analgesics/administration & dosage , Antibodies, Monoclonal/administration & dosage , Female , Greece/epidemiology , Headache/epidemiology , Humans , Implantable Neurostimulators/psychology , Implantable Neurostimulators/statistics & numerical data , Injections, Subcutaneous , Male , Middle Aged , Migraine Disorders/drug therapy , Migraine Disorders/epidemiology , Migraine Disorders/psychology , Preventive Medicine , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...